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Introduction
Neuropathic pain (NP) is a major disability in 
common neurological diseases, such as neuropathy, 
myelopathy, multiple sclerosis, or stroke (Table 1). 
Pain is complex sensation, strongly modulated by 
cognitive infl uences, and understading nocioceptive 
function and dysfunction is a hard task not only for 
„general“ neurologists but also for all pain special-
ists1-2. Th e distiction between nocioceptive and neuro-
pathic pain mechanisms is often a diffi  cult clinical ex-
ercise. Th e underlying pathophysiological mechanism 
that result in chronic pain can only be inferred, and 
this inference is based primarily on verbal description 
supported by examination and investigations2. NP is 
a neurological disorder with a high prevalence, thus it 
is essential that neurologists get involved in its diag-
nosis and manamgement1, and of course that not ex-
lude other specialists for this „job“, including phamily 
practitioners.
Table 1. Some common causes of neuropathic pain
Periferal nerve lesion or dysfunction
Painful diabetic neuropathy
Post-herpetic  neuralgia
Post-surgical pain (including post-mastectomy and 
phantom limb pain)
Complex regional pain syndrome
Trigeminal neuralgia
Chemotherapy-induced neuropathy
Neuropathy secondary to tumour infi ltration
Central nerve lesion or dysfunction
Central post-stroke pain
Multiple sclerosis pain
Spinal cord injury pain
Epidemiology
In 1991 Browsher3 suggested that the prevalence of 
neuropathic pain in the Unided Kingdom (UK) gen-
eral population was probably about 1% , and  in USA 
similar estimate was in 19971. A recent UK study1 
found that the population prevalence of chronic pain 
of predominantly neuropathic origin was 8.2% in 
adults, and it was concluded that neuropathic pain in 
the community seems to be more common than previ-
ously estimated. It assumed that prevalence of NP can 
be expected to increase in the future as the population 
ages.
Diagnosing neuropathic pain in clinical practice
Neuropathic pain can be diffi  cult to identify be-
cuse it is subjective, evidence of neuropathy does not 
always imply neuropathic pain, and multiple patho-
logical mechanisms ae variously expressed, some of 
which overlap with nocioceptive pain2.
Th e examination of a pain patient aims at clari-
fying underlying disease and understanding whether 
the pain is nocioceptive, neuropathic, psychogenic, or 
a combination of  such. In case of neuropathic pain, 
abnormal sensory fi nding should be neuroanatomi-
cally logical, compatible with a defi nite lesion site, 
and location, quality and intensity of pain should be 
assessed. It means that neurological examination in 
suspected neuropathic pain should include quantifi -
cation and maping of motor, sensory and autonomic 
phenomena to identify all signs of neurological dys-
function1.
Although there are no validated studies on bed-
side examination, good clinical practice teaches that 
in pain patients a through neurological examination 
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is invaluable – the sensory testing being the most im-
portant part of it – and is prleiminary to any quantita-
tive assessment1.
Quantitative sensory testing (QST) may be de-
fi ned as the analysis of perception in response to ex-
ternal stimuly of controlled intensity. So, QST mea-
sures detection thresholds (i.e. sensory responses) to 
thermal and electrical stimuli. Th e most sensitive of 
these is thermal threshold sesitivity (TTS) testing 
which involves the application of a thermode to the 
skin2. According to EFNS Panel on Neuropathic 
Pain1, although QST is not conclusive to demonstrate 
neuropathic pain, it is helpful to quantify the eff ects of 
treatments on allodynia and hyperalgesia. 
It is recommended to rate the intensity and the 
unpleasantness of pain separately5. Th e intensity of 
the diff erent pain components that the patient may 
report (spontaneous ongoing pain - burning or deep 
pressuure pain, spontaneous paroxysmal pain, dyses-
theseae, paresthesiae) or the evoked pains (allodynia 
and hyperalgesia), as wll as pain worsening with 
movement, should be rated separately, but using the 
sam scale. If diff erent pain components involve diff er-
ent territories, these can be documented on a template 
body map. Th e simlest scales are probably the best. 
Whereas verbal raing (VRS) scale is found to be easier 
by many patients, visual analog scale (VAS) is more 
apt to treatment trials because it permits parametric 
statistics. Th e Likert 0-10 numerical rating  is good 
compromise1.
Treatment of neuropathic pain 
Although monotherapy is the ideal approach, ratio-
nal polypharmacy is often pragmatically used. Several 
classes of drugs are moderately eff ective, but complete 
or near-complete relief is unlikely. Antidepressants 
and anticonvulsants are most commonly used. Opioid 
analgesics can provide some relief but are less eff ective 
than for nociceptive pain; adverse eff ects may prevent 
adequate analgesia. Topical drugs and a lidocaine-
containing patch may be eff ective for peripheral syn-
dromes. Sympathetic blockade is usually ineff ective 
except for some patients with complex regional pain 
syndrome (Ad hoc Committee of the Crotian Society 
for Neurovascular Disorders and Croatian Medical 
Association)6. According to EFNS Panel Neuropath-
ic Pain7. the main peripheral pain conditions respond 
similarly well to tryciclic antidepressants, gabapentin 
and pregabalin, but some conditions, such as HIV-
associated polyneuropathy, are more refractory. Th ere 
are only few studies on central pain, combination 
therapy, and head-to-head comparison. It is recom-
mended for future trials to assess quality of life and 
pain symptoms or signs with standardized tools.
Th is presentation gives an overview of diagnosing and 
treatment of neuropathic pain syndromes.
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